MedPath

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Phase 3
Completed
Conditions
Endometrial Cancer
Registration Number
NCT00006027
Lead Sponsor
Radiation Therapy Oncology Group
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor tissue. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if radiation therapy is more effective with or without combination chemotherapy for endometrial cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without combination chemotherapy following surgery in treating patients who have stage I or stage II endometrial cancer.

Detailed Description

OBJECTIVES:

* Compare the relapse-free survival in patients with stage I or II endometrial cancer treated with adjuvant radiotherapy with or without cisplatin and paclitaxel after total abdominal hysterectomy and bilateral salpingo-oophorectomy.

* Compare the patterns of recurrence and the acute and late toxicity profiles associated with these treatment regimens in this patient population.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease stage (IC-IIA vs IIB). Patients are randomized to one of two treatment arms.

* Arm I: Within 8 weeks after surgery, patients receive radiotherapy once daily 5 days a week for 5.5 weeks.

* Arm II: Within 8 weeks after surgery, patients receive radiotherapy as in arm I concurrently with cisplatin IV over 2-4 hours on days 1 and 28. After completion of radiotherapy, patients receive paclitaxel IV over 3 hours followed by cisplatin IV over 2-4 hours on days 56, 84, 112, and 140.

Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 436 patients (218 per treatment arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (29)

Jonsson Comprehensive Cancer Center, UCLA

🇺🇸

Los Angeles, California, United States

Community Hospital of Los Gatos

🇺🇸

Los Gatos, California, United States

Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center

🇺🇸

Orange, California, United States

University of Colorado Cancer Center at University of Colorado Health Sciences Center

🇺🇸

Denver, Colorado, United States

MBCCOP - Hawaii

🇺🇸

Honolulu, Hawaii, United States

Indiana University Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Holden Comprehensive Cancer Center at University of Iowa

🇺🇸

Iowa City, Iowa, United States

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

🇺🇸

Bethesda, Maryland, United States

Tufts - New England Medical Center

🇺🇸

Boston, Massachusetts, United States

University of Minnesota Cancer Center

🇺🇸

Minneapolis, Minnesota, United States

Scroll for more (19 remaining)
Jonsson Comprehensive Cancer Center, UCLA
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.